Our top pick for
Building a portfolio
Synthetic Biologics, Inc is a biotechnology business based in the US. Synthetic Biologics shares (SYN) are listed on the NYSE MKT and all prices are listed in US Dollars. Synthetic Biologics employs 11 staff and has a market cap (total outstanding shares value) of USD$7.4 million.
|Latest market close||USD$0.39|
|52-week range||USD$0.25 - USD$0.688|
|50-day moving average||USD$0.3414|
|200-day moving average||USD$0.4504|
|Wall St. target price||USD$1.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.123|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||N/A|
|1 month (2020-12-23)||8.33%|
|3 months (2020-10-19)||N/A|
|6 months (2020-07-19)||N/A|
|1 year (2020-01-19)||N/A|
|2 years (2019-01-19)||N/A|
|3 years (2018-01-19)||N/A|
|5 years (2016-01-19)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-50.27%|
|Return on equity TTM||-120.29%|
|Market capitalisation||USD$7.4 million|
TTM: trailing 12 months
There are currently 317,008 Synthetic Biologics shares held short by investors – that's known as Synthetic Biologics's "short interest". This figure is 799.7% up from 35,234 last month.
There are a few different ways that this level of interest in shorting Synthetic Biologics shares can be evaluated.
Synthetic Biologics's "short interest ratio" (SIR) is the quantity of Synthetic Biologics shares currently shorted divided by the average quantity of Synthetic Biologics shares traded daily (recently around 566085.71428571). Synthetic Biologics's SIR currently stands at 0.56. In other words for every 100,000 Synthetic Biologics shares traded daily on the market, roughly 560 shares are currently held short.
However Synthetic Biologics's short interest can also be evaluated against the total number of Synthetic Biologics shares, or, against the total number of tradable Synthetic Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Synthetic Biologics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Synthetic Biologics shares in existence, roughly 20 shares are currently held short) or 0.0159% of the tradable shares (for every 100,000 tradable Synthetic Biologics shares, roughly 16 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Synthetic Biologics.
Find out more about how you can short Synthetic Biologics stock.
We're not expecting Synthetic Biologics to pay a dividend over the next 12 months.
Synthetic Biologics's shares were split on a 1:35 basis on 13 August 2018. So if you had owned 35 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synthetic Biologics shares – just the quantity. However, indirectly, the new 3400% higher share price could have impacted the market appetite for Synthetic Biologics shares which in turn could have impacted Synthetic Biologics's share price.
Over the last 12 months, Synthetic Biologics's shares have ranged in value from as little as $0.25 up to $0.688. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Synthetic Biologics's is 2.2934. This would suggest that Synthetic Biologics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.